Skip Navigation Links  
 

ADNI Go Study



The Alzheimer’s Disease Neuroimaging Initiative (ADNI) began in October 2004 as a landmark study with a public-private partnership that gathered and analyzed thousands of brain scans, genetic profiles and biomarkers in blood and cerebrospinal fluid (CSF). Although the original goal was to define biomarkers for use in clinical trials to determine the best way to measure treatment effects of Alzheimer’s disease (AD), the goal has been expanded to using biomarkers to identify AD at a pre-dementia stage. ADNI involves scientists at 59 research centers, 54 in the U.S. and five in Canada. There are over 800 participants comprised of 200 with AD, 400 with mild cognitive impairment (MCI) and 200 with normal cognition.

Some of the leading-edge technologies under study are brain-imaging techniques, such as positron emission tomography (PET), including FDG-PET (which measures glucose metabolism in the brain); PET using a radioactive compound (PiB) that measures brain beta-amyloid; and structural MRI. Brain scans are showing scientists how the brain’s structure and function change as AD starts and progresses.

Biomarkers in cerebrospinal fluid are revealing other changes that could identify which patients with MCI will develop Alzheimer’s. Scientists are looking at levels of beta-amyloid and tau in cerebrospinal fluid. (Abnormal amounts of the amyloid and tau proteins in the brain are hallmarks of Alzheimer’s disease.)

The next step is to scan and analyze the brains of people with early mild cognitive impairment (eMCI). With a generous grant from American Recovery and Reinvestment Funds ADNI researchers will be able to study people with eMCI. This new grant expands the scope of ongoing research under ADNI by allowing for the enrollment of participants at an earlier stage of MCI, when symptoms are milder.

Furthermore, the funding for this new grant will allow ADNI investigators to extend the length of the original study to better assess changes in individuals over time. All of the participants will have neuroimaging scans and blood and cerebrospinal fluid analyses to look for changes in the brain.

The overall impact of the added funding will be increased knowledge of the sequence and timing of events leading to MCI and AD, development of better clinical and imaging/fluid biomarker methods for early detection and for monitoring the progression of these conditions. This will facilitate clinical trials of treatments to slow disease progression and will ultimately contribute to the prevention of AD.

In 2009, ADNI made a significant step forward in developing a test to help diagnose the beginning stages of AD sooner and more accurately by measuring levels of two biomarkers—tau and beta-amyloid proteins—in cerebrospinal fluid.

The following clinical research sites are taking part in ADNI and are looking for study participants.


U.S. Clinical Study Research Sites Participating in the ADNI GO Study:

SiteLocationTelephone #
Albany Medical College Albany, New York 518-262-3125
Banner Alzheimer's Institute Phoenix, Arizona 602-239-6900
Banner Sun Health Research Institute Sun City, Arizona 623-875-6500
Baylor College of Medicine Houston, Texas 713-798-4734
Boston University School of Medicine Boston, Massachusetts 617-638-5426
Brigham and Women's Hospital Boston, Massachusetts 617-732-8085
Butler Hospital Memory and Aging Program Providence, Rhode Island 401-455-6403
Case Western Reserve University Cleveland, Ohio 216-464-6474
Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas, Nevada 702-483-6026
Columbia University New York, New York 212-342-0522
Dartmouth-Hitchcock Medical Center Lebanon, New Hampshire 603-650-5811
Dent Neurological Group Amherst, New York 716-250-2038
Duke University Medical Center Durham, North Carolina 919-681-3949
Emory University Atlanta, Georgia 404-728-6950
Georgetown University Washington D.C., District of Columbia 202-784-6671
Howard University Washington D.C., District of Columbia 202-865-7895
Indiana University Indianapolis, Indiana 317-274-9903
Johns Hopkins University Baltimore, Maryland 410-550-6337
Mayo Clinic, Jacksonville Jacksonville, Florida 904-953-7897
Mayo Clinic, Rochester Rochester, Minnesota 507-284-1324
Medical University of South Carolina Charleston, South Carolina 843-740-1592 x14
Mount Sinai School of Medicine New York, New York 212-241-1514
New York University New York, New York 212-263-5708
Northwestern University Chicago, Illinois 312-503-2486
Ohio State University Columbus, Ohio 614-293-8531
Oregon Health and Science University Portland, Oregon 503-494-7615
Premiere Neurological Group West Palm Beach, Florida 561-845-0500 x211
Rhode Island Hospital Providence, Rhode Island 401-444-6440
Rush University Medical Center Chicago, Illinois 312-942-3033
Stanford University Palo Alto, California 650-849-0491
University of Alabama at Birmingham Birmingham, Alabama 205-934-3847
University of California, Davis Martinez, California 925-372-2485
University of California, Irvine Irvine, California 949-824-5733
University of California, Irvine - BIC Irvine, California 714-456-5697
University of California, Los Angeles Los Angeles, California 310-794-6191
University of California, San Diego San Diego, California 858-622-5800
University of California, San Francisco San Francisco, California 415-476-1676
University of Kansas Kansas City, Kansas 913-588-0555
University of Kentucky Lexington, Kentucky 859-323-6040
University of Michigan Ann Arbor, Michigan 734-647-7760
University of Pennsylvania Philadelphia, Pennsylvania 215-662-7810
University of Pittsburgh Pittsburgh, Pennsylvania 412-692-2700
University of Rochester Medical Center Rochester, New York 585-760-6550
University of Southern California Los Angeles, California 323-442-7600
University of Texas SWMC Dallas, Texas 214-648-9368
University of Wisconsin Madison, Wisconsin 866-636-7764
Wake Forest University Winston-Salem, North Carolina 336-713-8477
Washington University, St. Louis St. Louis, Missouri 314-286-2683
Wien Center Miami, Florida 305-674-2424
Yale University School of Medicine New Haven, Connecticut 203-764-8100


Canadian Clinical Study Research Sites Participating in the ADNI GO Study:

SiteLocationTelephone #
Jewish General Hospital / McGill University Montreal, Quebec 514-766-2010
Parkwood Hospital London, Ontario 519-685-4292 x42567
Saint Joseph's Hospital Hamilton, Ontario 519-646-6000 x64605
Sunnybrook Health Sciences Toronto, Ontario 416-480-6108
University of British Columbia Vancouver, British Columbia 604-822-7990